Andrea Tu, Author at Bolt Biotherapeutics

This author has yet to write their bio.
Meanwhile lets just say that we are proud Andrea Tu contributed a whooping 52 entries.

Publication

July 7, 2020 /0 Comments/in publications /by Andrea Tu

Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity Ackerman SE, et al., Nature Cancer (2020)

June 25, 2020 in podcast /by Andrea Tu

June 25, 2020 in media coverage /by Andrea Tu

Piramal Pharma Solutions and Bolt Biotherapeutics Sign Production Agreement ADC Review

June 24, 2020 in media coverage /by Andrea Tu

U.S. Patent for Bolt Biotherapeutics’ Boltbody™ ISAC Platform Technology is a Major Milestone in the Development of BDC-1001 ADC Review

June 24, 2020 in media coverage /by Andrea Tu

Randall Schatzman, Ph.D. to Lead Growth of Immune- Stimulating Antibody Conjugates at Bolt Biotherapeutics ADC Review

June 24, 2020 in media coverage /by Andrea Tu

How the Next Generation Antibody Drug Conjugates Expands Beyond Cytotoxic Payloads for Cancer Therapy ADC Review

June 23, 2020 in media coverage /by Andrea Tu

Bolt Biotherapeutics Nabs $93.5M to Push Provenge Inventor’s New Idea Deeper in the Clinic Endpoints News

June 22, 2020 in media coverage /by Andrea Tu

Bolt’s Myeloid Twist on ADCs Charged up with $93.5M series C BioCentury

June 22, 2020 in media coverage /by Andrea Tu

Pfizer-Backed Bolt Therapeutics Strikes $93.5M Funding Round As Lead Med Hits the Clinic Fierce Biotech

June 22, 2020 in media coverage /by Andrea Tu

Agonist ecstasy? HER2 (and more) ‘Bolt’-on strategy draws $93.5M series C BioWorld